Dr Mathilda Wilding

Dr Mathilda Wilding

Dr Mathilda Wilding
MBBS, FRACP (MedOnc, ClinGen), BMedSi, Cancer Geneticist

I am passionate about helping patients and their families better understand the importance of prevention and early diagnosis for cancer.

Languages spoken




North Shore
North Shore
-33.82024297423824, 151.19062046149045

Clinical interest in cancer genetics.

Dr Mathilda Wilding has been working in the field of cancer genetics since 2015. Mathilda is qualified as a specialist in medical oncology (cancer treatment) and clinical genetics. Mathilda is one of only a few doctors in Australia to have achieved both of these qualifications, and has been appointed as a cancer genetics consultant at Royal North Shore Hospital, Sydney.

Mathilda is a Fellow of the Royal College of Physicians (FRACP) and a member of the Human Genetics Society of Australia (HGSA). She is a member of the adult and paediatric cancer genetics reference committees for the National Cancer Institute (eviQ) guidelines. She is involved in developing evidence-based genetic testing and risk management guidelines, that are used Nationally and Internationally, to guide genetic testing and the management of individuals with an inherited cause of cancer.

A dedicated teacher, she supervises and mentors training doctors and genetic counsellors from hospitals across NSW.

Mathilda aims to be a caring and respectful clinician, supporting patients with evidence-based care.

Professional memberships

  • Human Genetics Society of Australia (HGSA)
  • Cancer Genetics Reference Committees for the National Cancer Institute (eviQ)
  • Fellow of Royal Australian College of Physicians (FRACP) 


  • Crook, A., Kwa, R., Ephraums, S., Wilding, M., Thiyagarajan, L., Fleming, J., ... & Berman, Y. (2021). The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1. Familial cancer, 1-13.
  • Benn, D. E., Zhu, Y., Andrews, K. A., Wilding, M., Duncan, E. L., Dwight, T., ... & Clifton-Bligh, R. J. (2018). Bayesian approach to determining penetrance of pathogenic SDH variants. Journal of medical genetics, 55(11), 729-734.